# SARC Regimen Reference Order: Temozolomide + Bevacizumab Protocol

**Document Type**: Hospital_Protocol  
**Institution**: SARC (Sarcoma Alliance for Research through Collaboration)
**Primary Indication**: Hemangiopericytoma and Malignant Solitary Fibrous Tumor
**Secondary Relevance**: Temozolomide + Bevacizumab dosing protocols applicable to GBM
**Treatment Schedule**: Every 28 days until disease progression or unacceptable toxicity
**CVAD Preference**: Preferred
**Keywords**: Temozolomide, Bevacizumab, Alternative Dosing Schedule, Sarcoma Protocol

## EXECUTIVE SUMMARY

This SARC protocol provides detailed **temozolomide** + **bevacizumab** combination therapy guidelines for hemangiopericytoma and malignant solitary fibrous tumor. While not directly indicated for GBM, the protocol offers valuable insights into alternative **temozolomide** scheduling (days 1-7 and 15-21) and lower-dose **bevacizumab** administration (5 mg/kg) that may be applicable to GBM treatment modifications.

---

## ALTERNATIVE DOSING SCHEDULE

### Temozolomide Protocol (Alternative to Standard GBM Dosing)
- **Dose**: 150 mg/m² PO daily
- **Schedule**: 
  - **Week 1**: Days 1-7 
  - **Week 3**: Days 15-21
  - **Administration**: Orally at bedtime on empty stomach
- **Available strengths**: 5 mg, 20 mg, 100 mg, 140 mg, 250 mg capsules
- **Classification**: Cytotoxic, Hazardous
- **Self-administration**: At home with pharmacy blister-pack dispensing

### Bevacizumab Protocol (Lower Dose Alternative)
- **Dose**: 5 mg/kg IV (vs standard 10 mg/kg in GBM)
- **Schedule**: Days 8 and 22 (between temozolomide cycles)
- **Administration**: IV in 100 mL normal saline over 10 minutes
- **Primary solution**: 500 mL normal saline on treatment days
- **Brand name requirement**: Prescription label must match specific brand ordered

---

## TREATMENT CYCLE COORDINATION

### 28-Day Cycle Structure
- **Days 1-7**: **Temozolomide** 150 mg/m² daily + ondansetron pre-medication
- **Day 8**: **Bevacizumab** 5 mg/kg IV (only if temozolomide completed days 1-7)
- **Days 9-14**: Treatment-free interval
- **Days 15-21**: **Temozolomide** 150 mg/m² daily + ondansetron pre-medication  
- **Day 22**: **Bevacizumab** 5 mg/kg IV (only if temozolomide completed days 15-21)
- **Days 23-28**: Treatment-free interval

### Treatment Dependency Rules
- **Day 8 bevacizumab**: Only administer if **temozolomide** taken on days 1-7
- **Day 22 bevacizumab**: Only administer if **temozolomide** taken on days 15-21
- **Rationale**: Ensures synchronized drug exposure and optimal efficacy

---

## LABORATORY MONITORING AND SAFETY PARAMETERS

### Pre-Treatment Requirements (Day 1)
- **Complete blood count**
- **Comprehensive biochemistry panel**
- **Liver function tests**
- **Urine protein assessment**
- **Baseline blood pressure**

### Treatment Proceeding Criteria

#### Days 1 and 15 (Temozolomide Days)
- **Absolute neutrophil count**: ≥1.0 × 10⁹/L
- **Platelet count**: ≥75 × 10⁹/L
- **Contact physician**: If parameters not met

#### Days 8 and 22 (Bevacizumab Days)  
- **Urine protein**: <1 g/L (based on Day 1 results)
- **Full vital signs**: Temperature, HR, RR, BP, O₂ saturation
- **No observation period**: Patient can be discharged immediately if stable

### Ongoing Monitoring
- **Day 15**: CBC as per physician orders
- **Proteinuria screening**: 
  - Lab urinalysis preferred
  - Dipstick acceptable if urinalysis unavailable
  - **Alert threshold**: ≥1 g/L protein or 2-3+ dipstick → notify prescriber

---

## ANTIEMETIC PROTOCOL

### Primary Antiemetic
- **Ondansetron 16 mg PO**
- **Timing**: 30 minutes prior to **temozolomide**
- **Schedule**: Days 1-7 and days 15-21
- **Self-administration**: At home
- **Patient instruction**: Take 30 minutes before bedtime with **temozolomide**

### Breakthrough Antiemetic
- **Metoclopramide 10-20 mg PO**
- **Schedule**: Every 4 hours as needed for nausea/vomiting
- **Home continuation**: Patient instructed to continue antiemetics at home

---

## DRUG PREPARATION AND HANDLING

### Temozolomide Handling
- **Dispensing method**: CCMB Pharmacy blister-pack system
- **Supply schedule**: One week blister card at a time
- **Dose rounding**: Automatic rounding within DSG Approved Dose Bands
- **Safe handling**: Cytotoxic precautions for 48 hours post-administration

### Bevacizumab Preparation
- **Brand name verification**: Critical safety requirement
- **Prescription matching**: Label must show prescribed brand name in brackets
- **Multiple manufacturers**: Several brands available, ensure correct selection
- **Dilution**: 100 mL normal saline
- **Infusion rate**: 10 minutes (rapid infusion vs standard 30-90 minutes)

---

## SAFETY MONITORING AND ALERTS

### Bevacizumab-Specific Risks
- **Hypertension**: Increased risk, monitor blood pressure
- **Post-operative bleeding**: Enhanced bleeding risk
- **Wound healing complications**: Delayed healing potential
- **Thromboembolic events**: Arterial and venous thrombosis risk

### Hypersensitivity Management
- **Protocol reference**: 'Hypersensitivity Reaction Standing Order'
- **Post-discharge monitoring**: Patient education on reaction symptoms
- **Immediate reporting**: Contact cancer team for any hypersensitivity symptoms

---

## PATIENT EDUCATION AND DISCHARGE INSTRUCTIONS

### Home Medication Management
1. **Timing coordination**: Ondansetron 30 minutes before **temozolomide**
2. **Administration timing**: **Temozolomide** at bedtime on empty stomach
3. **Nausea minimization**: Bedtime dosing reduces daytime nausea
4. **Antiemetic continuation**: Continue prescribed antiemetics at home

### Safety Precautions
- **Cytotoxic handling**: Safe handling precautions for blood/body fluids for 48 hours
- **Hypersensitivity awareness**: Immediate reporting of allergic reactions
- **Compliance importance**: Critical for treatment efficacy and safety

---

## CLINICAL IMPLICATIONS FOR GBM TREATMENT

### Previously Missing Clinical Information Now Available:

#### 1. **Alternative Temozolomide Scheduling**
- **Split-cycle dosing**: Days 1-7 and 15-21 vs continuous 1-5 days
- **Extended treatment intervals**: 14-day breaks between TMZ cycles
- **Dose consistency**: 150 mg/m² maintained throughout (no escalation to 200 mg/m²)

#### 2. **Lower-Dose Bevacizumab Protocol**
- **5 mg/kg dosing**: Half the standard GBM dose (10 mg/kg)
- **Rapid infusion**: 10 minutes vs standard 30-90 minutes
- **Frequent administration**: Every 2 weeks vs standard schedules

#### 3. **Synchronized Drug Administration**
- **Treatment dependency**: Bevacizumab only if TMZ completed
- **Optimal timing**: Bevacizumab between TMZ cycles for maximum synergy
- **Quality assurance**: Prevents incomplete treatment exposure

#### 4. **Practical Monitoring Thresholds**
- **Lower hematologic requirements**: ANC ≥1.0 × 10⁹/L, platelets ≥75 × 10⁹/L
- **Simplified proteinuria screening**: <1 g/L threshold with dipstick backup
- **Streamlined monitoring**: No observation period post-bevacizumab

#### 5. **Brand Name Verification Protocol**
- **Multiple bevacizumab manufacturers**: Critical safety consideration
- **Prescription accuracy**: Label verification requirements
- **Biosimilar considerations**: Ensuring therapeutic equivalence

#### 6. **Home-Based Oral Therapy Management**
- **Blister-pack dispensing**: Weekly supply system
- **Patient education focus**: Timing, administration, safety
- **Self-administration protocols**: Detailed home instructions

#### 7. **Rapid Bevacizumab Infusion Data**
- **10-minute infusion**: Significantly faster than standard protocols
- **Safety profile**: No extended observation required
- **Efficiency advantages**: Reduced infusion center time

---

## POTENTIAL GBM APPLICATIONS

### Clinical Scenarios Where SARC Protocol May Be Relevant:

#### 1. **Bevacizumab Dose De-escalation**
- Patients with hypertension or bleeding concerns
- Elderly patients requiring reduced intensity
- Maintenance therapy considerations

#### 2. **Alternative Temozolomide Scheduling**
- Patients with severe continuous dosing toxicity
- Extended treatment duration protocols  
- Optimization of drug-free intervals

#### 3. **Outpatient Management Enhancement**
- Home-based oral therapy programs
- Simplified monitoring schedules
- Patient convenience optimization

#### 4. **Resource Optimization**
- Reduced infusion center utilization
- Streamlined monitoring protocols
- Cost-effective treatment delivery

---

## COMPARATIVE ANALYSIS WITH STANDARD GBM PROTOCOLS

### Dosing Differences
| Parameter | SARC Protocol | Standard GBM Protocol |
|-----------|---------------|----------------------|
| **Temozolomide Dose** | 150 mg/m² (fixed) | 150→200 mg/m² (escalated) |
| **Temozolomide Schedule** | Days 1-7, 15-21 | Days 1-5 |
| **Bevacizumab Dose** | 5 mg/kg | 10 mg/kg |
| **Bevacizumab Infusion Time** | 10 minutes | 30-90 minutes |
| **Cycle Length** | 28 days | 28 days |
| **Treatment-Free Days** | 14 days per cycle | 23 days per cycle |

### Monitoring Differences
| Parameter | SARC Protocol | Standard GBM Protocol |
|-----------|---------------|----------------------|
| **ANC Threshold** | ≥1.0 × 10⁹/L | ≥1.5 × 10⁹/L |
| **Platelet Threshold** | ≥75 × 10⁹/L | ≥100 × 10⁹/L |
| **Proteinuria Threshold** | <1 g/L | <2 g/24hr |
| **Post-Infusion Observation** | None required | Variable |

This SARC protocol provides valuable alternative dosing and scheduling strategies for **temozolomide** and **bevacizumab** combination therapy that may be applicable to GBM patients requiring dose modifications, alternative schedules, or enhanced outpatient management approaches.